African-Americans with RRMS Show Preference for Oral Gilenya in Phase 4 Trial, Study Reports


African-Americans with relapsing–remitting multiple sclerosis (RRMS) show higher adherence and greater satisfaction when treated with oral Gilenya (fingolimod, by Novartis) than with injectable therapies, according to a new study.

The research, “Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study,” was published in the journal Multiple Sclerosis and Related Disorders.

Although the efficacy and safety of injectable disease-modifying therapies (iDMTs) used as first-line treatments for relapsing forms of MS are well-established, patients are also known from real-world studies to often discontinue using them and become non-adherent to these therapies. Research has shown that…

Read More


320ro

Comments

comments